Foghorn Therapeutics reported a significant increase in collaboration revenue to $83.5 million for the third quarter of 2026, resulting in a net income of $58.2 million compared to a net loss in the prior year. The company also improved its stockholders' deficit from $108.5 million at the end of 2025 to $14.1 million as of September 30, 2026.
Foghorn Therapeutics reported Q3 2026 financial results, highlighted by a significant increase in collaboration revenue to $83.5 million due to a cumulative catch-up adjustment. The company reported a net income of $44.5 million for the quarter and maintains a cash runway into the second half of 2029 to support its oncology and immunology pipelines.
“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year. We are also advancing a novel induced-proximity approach with the potential to deliver antibody-like efficacy against high-value secreted and transmembrane proteins through small molecules. With cash runway into the second half of 2029, we are well positioned to deliver on this strategy.”
Adrian Gottschalk, President and Chief Executive Officer